The immunogenicity of tumor cell death

Current Opinion in Oncology

Volumn 21, Issue 1, 2009, Pages 71-76

  Kepp, Oliver ^a,b,c   Tesniere, Antoine ^a,b,c   Zitvogel, Laurence ^a,b,c,d   Kroemer, Guido ^a,b,c  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d CIC BT507   (France)

Author keywords

Anthracyclines; Calreticulin; Cancer immunity

Indexed keywords

ANTHRACYCLINE; BORTEZOMIB; CALRETICULIN; CASPASE; DNA; DOXORUBICIN; ETOPOSIDE; HIGH MOBILITY GROUP B1 PROTEIN; MITOMYCIN C; OXALIPLATIN; STAUROSPORINE; TOLL LIKE RECEPTOR 4;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; ANTIGEN PRESENTATION; APOPTOSIS; CANCER IMMUNOLOGY; CANCER THERAPY; CELL ACTIVATION; CELL DEATH; CELL MATURATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA DAMAGE; DRUG EFFICACY; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; FIBROSARCOMA; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSURVEILLANCE; IONIZING RADIATION; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; APOPTOSIS; DENDRITIC CELLS; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 58149262973     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32831bc375     Document Type: Review

References (33)

1. Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202:1691-1701.
2. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999; 5:1249-1255.
3. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392:86-89.
4. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the •• immunogenicity of cancer cell death. Nat Med 2007; 13:54-61. This study shows a preapoptotic translocation of CRT to the plasma membrane, which facilitates the engulfment of CRT-exposing tumor cells by dendritic cells.
5. Obeid M, Panaretakis T, Joza N, et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 2007; 14:1848-1850.
6. Kroemer G, Zitvogel L. Death, danger, and immunity: an infernal trio. Immunol Rev 2007; 220:5-7.
7. Stagg J, Johnstone RW, Smyth MJ. From cancer immunosurveillance to cancer immunotherapy. Immunol Rev 2007; 220:82-101.
8. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent •• contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13:1050-1059. The authors show that HMGB1, secreted by dying tumor cells, acts on TLR4 of dendritic cells to stimulate tumor antigen specific T-cell immunity.
9. Obeid M, Tesniere A, Panaretakis T, et al. Ecto-calreticulin in immunogenic chemotherapy. Immunol Rev 2007; 220:22-34.
10. Apetoh L, Ghiringhelli F, Tesniere A, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007; 220:47-59.
11. Zitvogel L, Apetoh L, Ghiringhelli F, et al. The anticancer immune response: indispensable for therapeutic success? J Clin Invest 2008; 118:1991-2001.
12. Gardai SJ, Bratton DL, Ogden CA, Henson PM. Recognition ligands on apoptotic cells: a perspective. J Leukoc Biol 2006; 79:896-903.
13. Chaput N, De Botton S, Obeid M, et al. Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. J Mol Med 2007; 85:1069-1076.
14. Tufi R, Panaretakis T, Bianchi K, et al. Reduction of endoplasmic reticulum Ca2+ levels favors plasma membrane surface exposure of calreticulin. Cell Death Differ 2008; 15:274-282.
15. Panaretakis T, Joza N, Modjtahedi N, et al. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 2008; 15:1499-1509.
16. Hickman-Miller HD, Hildebrand WH. The immune response under stress: the role of HSP-derived peptides. Trends Immunol 2004; 25:427-433.
17. Spisek R, Charalambous A, Mazumder A, et al. Bortezomib enhances den- • dritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 2007; 109:4839-4845. The authors show that the surface exposure of HSP90 is a relevant player in tumor immunogenicity.
18. Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 2007; 220:35-46.
19. Kazama H, Ricci JE, Herndon JM, et al. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 2008; 29:21-32.
20. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8:59-73.
21. Tesniere A, Panaretakis T, Kepp O, et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 2008; 15:3-12.
22. Bottazzi B, Garlanda C, Salvatori G, et al. Pentraxins as a key component of innate immunity. Curr Opin Immunol 2006; 18:10-15.
23. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anticancer barrier in early human tumorigenesis. Nature 2005; 434:864-870.
24. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is •• triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445:656-660. This study determines the function of p53 in cellular senescence associated with the up-regulation of inflammatory cytokines and tumor clearance.
25. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005;436:1186-1190.
26. Guerra N, Tan YX, Joncker NT, et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008; 28:571-580.
27. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285:727-729.
28. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002; 2:850-861.
29. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6:715-727.
30. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008; 13:472-482.
31. Fischer K, Hoffmann P, Voelkl S, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 2007; 109:3812-3819.
32. Munn DH, Mellor AL Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007; 117:1147-1154.
33. Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and noncanonical NF-kappaB activation. Nat Rev Immunol 2007; 7:817-823.